Price$3.84-0.06 (-1.54%)
04:15 PM07:45 PM
News · 26 weeks38+900%
2026-03-012026-08-23
Mix1190d
- Insider6(55%)
- SEC Filings2(18%)
- Other2(18%)
- Offering1(9%)
Latest news
25 items- PRAdagene to Participate in Three Upcoming Investor ConferencesSAN DIEGO and SUZHOU, China, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (NASDAQ:ADAG) a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced that senior management will participate in three upcoming investor conferences taking place in New York, New York. 2026 Cantor Global Healthcare Conference; New York, NY – September 9-11, 2026 Format: 1x1 MeetingsDate/Time: September 11, 2026 Morgan Stanley 24th Annual Global Healthcare Conference; New York, NY – September 14-16, 2026 Format: Fireside Chat and 1x1 MeetingsFireside Chat Date/Time: September 15, 2026, 10:45–11:20 AM (Eastern Time) H.
- INSIDERDirector Do Cuong V bought $7,500 worth of American Depositary Shares (2,000 units at $3.75) (SEC Form 4)4 - Adagene Inc. (0001818838) (Issuer)
- INSIDERSEC Form 4 filed by Director Zhu Li4 - Adagene Inc. (0001818838) (Issuer)
- INSIDERSEC Form 4 filed by Director Cheung Andy Yiu Leung4 - Adagene Inc. (0001818838) (Issuer)
- INSIDERSEC Form 4 filed by Director Do Cuong V4 - Adagene Inc. (0001818838) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Adagene Inc.SCHEDULE 13G/A - Adagene Inc. (0001818838) (Subject)
- INSIDERSEC Form 4 filed by Director Grawunder Ulf4 - Adagene Inc. (0001818838) (Issuer)
- SECSEC Form 6-K filed by Adagene Inc.6-K - Adagene Inc. (0001818838) (Filer)
- PRAdagene Reports Six Months 2026 Financial Results and Provides Corporate UpdatesRandomized Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC) ongoing, with results expected in 1H 2027; potential registration trial expected in 2027 once recommended dose regimen has been established Data reported at AACR from triple combination therapy in 1L hepatocellular carcinoma (HCC) and late-line MSS CRC highlights muzastotug’s potential as a backbone combination treatment for multiple tumor types across all lines of therapy Initiated dosing in a global Phase 1/2 basket trial evaluating muzastotug in combination with a next-generation investigational IO agent through a clinical collaboration with Sanofi Investigator-initiated Phase 2 trial of muzastotug in neoa
- INSIDERChief Executive Officer Luo Peter bought $84,764 worth of American Depositary Shares (23,245 units at $3.65), increasing direct ownership by 52% to 68,245 units (SEC Form 4)4 - Adagene Inc. (0001818838) (Issuer)
- SECSEC Form 6-K filed by Adagene Inc.6-K - Adagene Inc. (0001818838) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Adagene Inc.SCHEDULE 13G/A - Adagene Inc. (0001818838) (Subject)
- PRAdagene to Participate in Two Upcoming Investor ConferencesSAN DIEGO and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene or the Company") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that senior management will participate in one-on-one investor meetings and a fireside chat at the Stifel Annual Virtual Oncology Event on May 19-20, 2026 and one-on-one investor meetings at the Jefferies LLC Global Healthcare Conference being held June 2-4, 2026 in New York, NY. Stifel Annual Virtual Oncology Event Format: Fireside Chat and 1x1 MeetingsDate/Time: Tuesday, May 19, 2026, at 2:30 PM (Eastern Time)Webcast: Link here Jefferies LLC Global Healthcare
- SECSEC Form SCHEDULE 13G filed by Adagene Inc.SCHEDULE 13G - Adagene Inc. (0001818838) (Subject)
- SECSEC Form 6-K filed by Adagene Inc.6-K - Adagene Inc. (0001818838) (Filer)
- PRAdagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug's Potential as a Backbone Combination Therapy for Multiple Tumor TypesTriple combination of muzastotug + atezolizumab + bevacizumab resulted in much higher overall response rates (ORR) compared to the atezolizumab + bevacizumab control arm (66.7% vs. 32.5%, respectively by Investigator per HCC-specific Modified RECIST v1.1) as 1L therapy in a Phase 1b/2 trial in locally advanced or metastatic and/or unresectable hepatocellular carcinoma (HCC) patients Triple combination of muzastotug + pembrolizumab + fruquintinib exhibited a dose-dependent response (25% and 40% ORR for 10 mg/kg and 15 mg/kg, respectively) in a Phase 1b/2 trial in late-line microsatellite stable colorectal cancer (MSS CRC) patients New data are further evidence that muzastotug's masking tech
- PRAdagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory BoardSAN DIEGO and SUZHOU, China, April 14, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced the addition of Peter Lebowitz, MD, Ph.D. to its Scientific and Strategic Advisory Board (SAB). Regarding his appointment to Adagene's SAB, Lebowitz added, "Adagene's proprietary SAFEbody masking technology represents an innovative approach to addressing the historical limitations of CTLA-4–targeted therapies by enabling tumor-selective activation of ADG126 and focused depletion of intratumoral regulatory T cells. The encouraging clinical
- SECSEC Form 424B5 filed by Adagene Inc.424B5 - Adagene Inc. (0001818838) (Filer)
- SECSEC Form 6-K filed by Adagene Inc.6-K - Adagene Inc. (0001818838) (Filer)
- PRAdagene Announces Pricing of US$70.0 Million Public Offering of ADSsSAN DIEGO and SUZHOU, China, April 02, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene" or the "Company") (NASDAQ:ADAG), a company committed to transforming the discovery and development of novel antibody-based therapies, today announced the pricing of its underwritten public offering of 18,666,000 American depositary shares, or ADSs, each representing 1.25 ordinary shares of the Company, par value US$0.0001 per share, at the offering price of US$3.75 per ADS, representing the 30-day volume-weighted average price ("VWAP"). The gross proceeds to Adagene from the offering are expected to be approximately US$70.0 million, before deducting underwriting discount and offering expenses. The offe
- SECSEC Form 424B5 filed by Adagene Inc.424B5 - Adagene Inc. (0001818838) (Filer)
- PRAdagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte's TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)Phase 1 study of INCA33890 and muzastotug expected to begin in 2026 in 3L MSS CRC patients with and without liver metastases Study will be sponsored and conducted by Incyte; Adagene to provide clinical supply of muzastotug Collaboration provides additional validation of muzastotug as a potential backbone therapy for next-generation immuno-oncology combinations SAN DIEGO and SUZHOU, China, April 02, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced a clinical collaboration with Incyte (NASDAQ:INCY), to evaluate the combination of muzastotug (ADG126) and INCA33890, a TGF
- SECSEC Form 6-K filed by Adagene Inc.6-K - Adagene Inc. (0001818838) (Filer)
- PRUpdated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of ResponseDose-Dependent Efficacy Results: As of the latest data cut, muzastotug achieved a 31% (8/26) confirmed overall response rate (ORR) in the combined 20 mg/kg dose cohorts, showing a clear improvement over the 13% ORR (5/39) in the combined 10 mg/kg dose cohorts Extended Durability: Median duration of response (mDOR) was not yet reached in the 20 mg/kg cohorts, with responses ongoing beyond 9 months; confirmed mDOR of 6.2 months in the 10 mg/kg cohorts Meaningful Progression-Free Survival (PFS): Median PFS was 6.7 months in the combined 20 mg/kg cohorts, outperforming the 4.8 months observed in the combined 10 mg/kg cohorts Favorable Overall Survival Results: In the 10 mg/kg cohorts (n=41;
- SECSEC Form 6-K filed by Adagene Inc.6-K - Adagene Inc. (0001818838) (Filer)
ADAG FAQ
7 questionsWhat does Adagene Inc. do?
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for...Where does ADAG stock trade?
Adagene Inc. (ADAG) is listed on NASDAQ.What sector and industry is ADAG in?
Adagene Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Adagene Inc. go public?
Adagene Inc. (ADAG) completed its IPO in 2021.What are analysts saying about ADAG?
Adagene Inc. has had 4 recent analyst actions on file. The most recent action was from Guggenheim: Buy with a $900.00 price target on 2025-11-24. Recent price targets range from $700.00 to $1500.00.What companies are similar to ADAG?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ADAG side-by-side with any of them on Quantisnow.How can I track ADAG on Quantisnow?
Quantisnow aggregates Adagene Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ADAG to receive live email and push alerts on every new disclosure.